uniQure (NASDAQ:QURE) Shares Down 7.3% Following Analyst Downgrade

uniQure (NASDAQ:QURE)’s stock price traded down 7.3% on Monday after Wells Fargo & Company lowered their price target on the stock from $35.00 to $30.00. Wells Fargo & Company currently has an equal weight rating on the stock. uniQure traded as low as $12.22 and last traded at $12.19. 151,018 shares changed hands during trading, a decline of 85% from the average session volume of 1,001,427 shares. The stock had previously closed at $13.15.

QURE has been the subject of several other reports. The Goldman Sachs Group raised their target price on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, February 5th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Finally, Leerink Partners raised their target price on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 6,717 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the sale, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christian Klemt sold 14,341 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the sale, the chief financial officer now directly owns 152,372 shares in the company, valued at $1,630,380.40. This represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 55,915 shares of company stock worth $588,112 over the last ninety days. 4.74% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently modified their holdings of QURE. Atria Investments Inc acquired a new position in uniQure during the third quarter valued at approximately $53,000. Privium Fund Management B.V. lifted its position in uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after buying an additional 104,500 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in uniQure during the third quarter valued at approximately $69,000. Charles Schwab Investment Management Inc. lifted its position in uniQure by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock valued at $1,367,000 after buying an additional 16,464 shares in the last quarter. Finally, FMR LLC lifted its position in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after buying an additional 346,274 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Trading Up 3.9 %

The stock has a market capitalization of $552.26 million, a price-to-earnings ratio of -2.28 and a beta of 0.38. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The business’s 50-day simple moving average is $14.80 and its two-hundred day simple moving average is $9.89.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.